Psmc2, Proteasome 26S subunit, ATPase 2, is an essential part of the 26S proteasome, which is involved in the ubiquitin-proteasome system that catalyzes the unfolding and transport of substrates into the 20S proteasome [5]. It has been implicated in multiple biological processes and is associated with several pathways, such as the PI3K/Akt/mTOR pathway [4].

Knockdown of Psmc2 in various cancer cell lines and in vivo tumor xenograft models has shown significant anti-tumor effects. In oral squamous cell carcinoma, Psmc2 knockdown inhibited cell proliferation, migration, and promoted apoptosis via the PI3K/Akt pathway [1]. Similar results were found in glioma, gastric cancer, skin cutaneous melanoma, nasopharyngeal carcinoma, pancreatic cancer, ovarian cancer, and hepatocellular carcinoma, where Psmc2 knockdown suppressed cell proliferation, migration, and induced apoptosis. In gastric cancer, Psmc2 promoted cancer progression through the RPS15A/mTOR pathway [2]. In glioma, it regulated the immune microenvironment and the PI3K/AKT/mTOR pathway [4]. In skin cutaneous melanoma, it was involved in the Wnt signaling pathway [3].

In conclusion, Psmc2 plays a crucial role in promoting the progression of multiple cancers, mainly by regulating cell proliferation, apoptosis, migration, and related signaling pathways. The knockdown models of Psmc2 have provided valuable insights into the molecular mechanisms of cancer development, suggesting that targeting Psmc2 could be a potential therapeutic strategy for these cancers.